Veru Inc.

VERU

US92536C1036

Personal Products

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
0.9471 ^USD	+1.69%		-0.56%	+31.54%

Jul. 01	Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Value Index	CI
Jul. 01	Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Completeness Index	CI

The Female Health Company’s Equity Buyback Plan extended till December 31, 2013

January 02, 2013

On January 3, 2013, the Board of Directors extended the share repurchase program until December 31, 2013.

Latest news about Veru Inc.

Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Completeness Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Growth Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000E Growth Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Growth Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2000 Dynamic Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Microcap Value Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Growth Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell Small Cap Comp Growth Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 2500 Index	Jun. 30	CI
Veru Inc.(NasdaqCM:VERU) added to Russell 3000 Index	Jun. 30	CI
Veru Inc. to Present an Update of Veru's Phase 2B Clinical Program of Enobosarm to Augment Fat Loss and to Avoid Muscle Loss When Combined with GLP-1 Drugs for Weight Loss At the Jefferies Global Healthcare Conference	May. 22	CI
B. Riley Securities Starts Very With Buy Rating, $5 Price Target	May. 14	MT
Veru Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	May. 08	CI
Earnings Flash (VERU) VERU Posts Q2 Revenue $4.1M	May. 08	MT
Transcript : Veru Inc., Q2 2024 Earnings Call, May 08, 2024	May. 08
HC Wainwright Adjusts Veru Price Target to $3 From $2, Maintains Buy Rating	May. 06	MT
Veru Inc. Enrolls First Patients in Phase 2b Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss	Apr. 30	CI
Oppenheimer Cuts Veru Price Target to $5 From $7, Maintains Outperform Rating	Apr. 15	MT

Veru Inc. is a biopharmaceutical company. The Company is focused on developing medicines for the for the treatment of hospitalized COVID-19 patients at high risk for acute respiratory distress syndrome (ARDS) and other viral-related ARDS and for the management of breast and prostate cancers. The Company offers two FDA approved products within its sexual health program, including ENTADFI (tadalafil 5mg and finasteride 5mg capsule), for the treatment of benign prostatic hyperplasia and FC2 Female Condom (internal condom) (FC2), for the dual protection against unplanned pregnancy and the transmission of sexually transmitted infections. Its breast cancer drug pipeline has four clinical development programs for two drugs, such as enobosarm, an oral selective androgen receptor targeting agonist, and sabizabulin, an oral cytoskeleton disruptor. Its prostate cancer drug pipeline includes sabizabulin, VERU-100 and zuclomiphene citrate.

Sector

Personal Products

Calendar

2024-08-07 - Q3 2024 Earnings Release (Projected)

More about the company